Modality
mRNA
MOA
EZH2i
Target
IL-13
Pathway
Complement
RSV
Development Pipeline
Preclinical
Jul 2017
→ Jun 2028
PreclinicalCurrent
NCT05980363
2,389 pts·RSV
2017-07→2028-06·Not yet recruiting
2,389 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-05-031mo awayOrphan Drug· RSV
2028-06-112.2y awayInterim· RSV
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
Preclinical
Not yet…
Catalysts
Orphan Drug
2026-05-03 · 1mo away
RSV
Interim
2028-06-11 · 2.2y away
RSV
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05980363 | Preclinical | RSV | Not yet recr... | 2389 | SRI-4 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Lisonaritide | Eli Lilly | Phase 3 | IL-13 | |
| Adagrazumab | Novartis | Phase 2/3 | Cl18.2 | |
| Ribotuximab | Merck & Co | Phase 2 | GPRC5D | |
| Sovarapivir | AbbVie | Phase 2/3 | IL-13 | |
| Ceviderotide | Novo Nordisk | Preclinical | IL-13 | |
| NVO-9615 | Novo Nordisk | Phase 2/3 | PRMT5 | |
| DSN-3066 | Daiichi Sankyo | Phase 3 | IL-13 | |
| MRN-7601 | Moderna | Phase 2 | IL-13 | |
| Polalucimab | Jazz Pharma | Preclinical | PLK4 | |
| ASN-7038 | Ascendis Pharma | Phase 3 | VEGF |